論文 - 佐治 重衡
-
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N, Saji S, Miyoshi Y, Bardia A, Harbeck N, Haiderali A, Fan L, Mejia JA, Karantza V, Llombart-Cussac A
Clin Cancer Res 32 ( 5 ) 883 - 893 2026年3月
-
放射線による健康影響不安を考慮したAYA世代がん患者のピアサポート 福島県出身AYA世代がん体験者の現状
桜井なおみ, 駒形 千鶴子, 白浜 若菜, 木村 礼子, 佐治 重衡
AYAがんの医療と支援 6 ( 1 ) 34 - 40 2026年2月
-
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
Wildiers H, Adam V, O'Reilly S, Van Cauwenberge J, Arahmani A, Arteaga CL, Bedard PL, Bliss J, Boussis P, Brain E, Buyse M, Caballero C, Cameron D, Cardoso F, Carrasco E, Casas A, Chua B, Curigliano G, DeMichele A, Esserman L, Floris G, Goetz MP, Goulioti T, Haibe-Kains B, Hodgdon C, Ignatiadis M, Kok M, Lacombe D, Linderholm B, Loi S, Lord CJ, MacKenzie M, Maues J, Meheus L, Needham J, Neven P, Parsons H, Piccart M, Pusztai L, Razis E, Saji S, Schumacher-Wulf E, Sonke GS, Spanic T, Tannock IF, Tutt A, Urruticoechea A, van 't Veer L, Vaz-Luis I, Werutsky G, Yee D, Zaman K, Desmedt C
JAMA Oncol 12 ( 2 ) 200 - 207 2026年2月
-
Postmastectomy radiation therapy for autologous breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline
Ogita M, Sawayanagi S, Jinnouchi H, Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamura M, Yamamoto Y, Saji S, Toyama T
Breast Cancer 33 ( 1 ) 1 - 9 2026年1月
-
Author Correction: Advancing equitable access to innovation in breast cancer
O'Reilly S, Luis IV, Adam V, Razis ED, Urruticoechea A, Arahmani A, Carrasco E, Chua BH, Bliss J, Straehle C, Goulioti T, Lindholm B, Werutsky G, Brain E, Bedard PL, Curigliano G, Loi S, Saji S, Cameron D.
NPJ Breast Cancer 11 ( 1 ) 140 2025年12月
-
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP; Panelists of the St. Gallen International Breast Cancer Consensus 2025
Ann Oncol 36 ( 12 ) 1433 - 1446 2025年12月
-
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study
Shibata N, Kuwazawa H, Yasukawa T, Iwabuchi M, Saji S.
Support Care Cancer 33 ( 12 ) 1115 2025年11月
-
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study
Ozaki Y, Tokuda E, Sagara Y, Hara F, Sasada S, Sawaki M, Kanbayashi C, Yamanaka T, Onishi T, Fujiki Y, Suto A, Takahashi Y, Tokunaga E, Aruga T, Nakamura R, Fujisawa T, Saji S, Iwata H, Shien T
ESMO Open 10 ( 11 ) 105889 2025年11月
-
Timing of postmastectomy radiation therapy in two-stage expander/implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese breast cancer society clinical practice guideline
3. Ogita M, Sawayanagi S, Jinnouchi H, Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamura M, Yamamoto Y, Saji S, Toyama T
Breast Cancer 32 ( 6 ) 1159 - 1168 2025年11月
-
Postmastectomy radiation therapy for implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline
2. Ogita M, Sawayanagi S, Jinnouchi H, Yoshimura M, Yamauchi C, Sanuki N, Hamamoto Y, Hirata K, Kawamura M, Yamamoto Y, Saji S, Toyama T
Breast Cancer 32 ( 6 ) 1169 - 1179 2025年11月
-
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey
NPJ Breast Cancer 11 ( 1 ) 113 2025年10月
-
Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese national clinical database-breast cancer registry
Ogita M, Kumamaru H, Kubo M, Kinukawa N, Niikura N, Saji S, Toi M
Breast 83 104567 2025年10月
-
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)
6. Bando H, Ueda A, Terata K, Doi M, Nagai SE, Hattori M, Watanabe K, Tamura N, Futamura M, Koizumi K, Niikura N, Miyaji T, Muramatsu Y, Xu L, Masuda N, Saji S
Breast Cancer 32 ( 5 ) 1132 - 1143 2025年9月
-
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial
7. Shien T, Hara F, Aogi K, Yanagida Y, Tsuneizumi M, Yamamoto N, Matsumoto H, Suto A, Watanabe K, Harao M, Kanbayashi C, Itoh M, Kadoya T, Anan K, Maeda S, Sasaki K, Ogawa G, Saji S, Fukuda H, Iwata H; JCOG Breast Cancer Study Group.
Br J Cancer 133 ( 5 ) 625 - 632 2025年9月
-
Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan
8. Miyashita M, Kumamaru H, Hayashi N, Kimura F, Yamamoto H, Niikura N, Sagara Y, Jinno H, Toi M, Saji S
Breast Cancer 32 ( 5 ) 947 - 959 2025年9月
-
Comparison of Effectivity and Safety of Olanzapine and Mirtazapine on Cancer-Associated Anorexia and Cachexia in Advanced Oral Cavity Cancer Patients: Prospective, Comparative, Interventional Study
9. Singhal Y, Pingoliya SK, Gaurav R P, Saji S, Sharma A
J Pain Palliat Care Pharmacother 39 ( 3 ) 432 - 441 2025年9月
-
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer
10. Yoshinami T, Takano Y, Ozaki Y, Kajiwara Y, Yamamoto M, Watanabe KI, Tsukabe M, Fujisawa F, Nagai SE, Shibata N, Oshiro C, Bando H, Tsunoda N, Yamagami K, Koizumi K, Takada M, Toriguchi N, Sekine N, Kawaguchi T, Saji S, Sagara Y, Morita S, Masuda N.
Breast Cancer 32 ( 5 ) 1157 - 1158 2025年9月
-
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet 406 ( 10503 ) 603 - 614 2025年8月
-
Risk factors for early mortality among patients with gastrointestinal malignancy in the C-CAT database.
Suzuki R, Shimizu H, Sato K, Asama H, Ohira R, Sugimoto M, Saito R, Okano M, Kimura-Tsuchiya R, Satio M, Saji S, Takagi T, Ohira H
International journal of clinical oncology 30 ( 8 ) 1593 - 1601 2025年8月（ ISSN:1341-9625 ）
-
Advancing equitable access to innovation in breast cancer.
O'Reilly S, Luis IV, Adam V, Razis ED, Urruticoechea A, Arahmani A, Carrasco E, Chua BH, Bliss J, Straehle C, Goulioti T, Lindholm B, Werustsky G, Brain E, Bedard PL, Curigliano G, Loi S, Saji S, Cameron D
NPJ breast cancer 11 ( 1 ) 71 2025年7月（ ISSN:2374-4677 ）